Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hypoxic cells within tumors represent a microenvironment with low oxygen levels that can be exploited for targeted therapy and imaging. Bioreductive trapping leverages the preferential enzymatic reduction of certain molecules (e.g., nitroimidazoles) under hypoxic conditions. This process leads to the formation of reactive intermediates that covalently bind to intracellular macromolecules, resulting in their selective retention and/or activation of cytotoxic agents within hypoxic cells, thereby targeting these treatment-resistant cells while sparing normal tissue.
Enzymatic reduction of compounds in hypoxic conditions, leading to covalent binding to intracellular macromolecules and selective accumulation/activation of cytotoxic agents.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypoxic Cell (Bioreductive Trapping).